Medindia
Medindia LOGIN REGISTER
Advertisement

HeartWare to Report Financial Results for First Quarter of 2010

Tuesday, April 13, 2010 General News
Advertisement


FRAMINGHAM, Mass. and Sydney, April 12 HeartWare International, Inc. (Nasdaq: HTWR; ASX:HIN) will release financial results for the first quarter ended March 31, 2010 after the close of the U.S. markets on Monday, May 3, 2010.
Advertisement

A conference call with management is scheduled for 5:00 pm U.S. Eastern Time on Monday, May 3, 2010 (being 7:00 am Australian Eastern Standard Time on Tuesday, May 4, 2010) to discuss the Company's financial results and to provide a corporate update. The call may be accessed by dialing 1-877-407-4018 five minutes prior to the scheduled start time and referencing "HeartWare." For callers outside the United States, dial + 1-201-689-8471.
Advertisement

A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare First Quarter Conference Call" under the section titled "Corporate Presentations" on the Home Page. A replay of the conference call will be available through the above weblink immediately following completion of the call.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare System in the European Union. The device is currently the subject of a United States clinical trial for a bridge-to-transplant indication with enrollment completed in February 2010. For additional information, please visit the company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information: ------------------------ Christopher Taylor HeartWare International, Inc. Email: [email protected] Phone: +1 508 739 0864

SOURCE HeartWare International, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close